Samples #15399 and #15400 were submitted together. Sample #15400 is a purplish crystalline powder (pictured above), and sample #15399 is a soft white powder.
Two submission forms were submitted with these samples, one for material sold as MDMA and described as ''white powder/crystals blue tint'', and the other one for material sold as 2C-B and described as ''white powder''.
The submission form for the material sold as MDMA and described as ''white powder/crystals blue tint'' accompanied the soft white powder. The material sold as 2C-B and described as ''white powder'' accompanied the purplish/brownish crystalline powder.
Because of the actual content of these two powders -- GC/MS showed the purplish/brownish crystalline powder to be MDMA, and the soft white powder to be 2C-B -- it is the DrugsData crew's belief that each submission form arrived at the lab accompanying the wrong powder, that they effectively arrived switched.
We've confirmed these are a sample of MDMA and a sample of 2C-B. If you sent in these two samples, the descriptions of the physical characteristics of the powders might reassure you that the submission forms were switched. Or, you can reagent-test them to distinguish the MDMA from the 2C-B to be double sure.
*tl;dr This purplish crystalline powder, confirmed to be MDMA, arrived at the lab with a submission form for a sample sold as 2C-B.*
Contact info (at) drugsdata (dot) org about samples #15399 and #15400 if you have any questions.
Send in a sample for testing
DrugsData tests all psychoactive drugs including ecstasy tablets, powders, research chemicals, novel pschoactive substances, and other drugs through our licensed laboratory. Ecstasy/Molly tablets cost $100. Recreational drug powder/crystal/blotter costs $100. Pharmaceuticals, supplements and all others cost $150 per analysis.
Should the public have access to independent analysis of the products they consume?
The vast majority of analyses of over-the-counter, prescription, and recreational drugs are performed in secret with no independent oversite or review. No other historical record, free from politically-controlled agencies, is currently available in North America nor most other parts of the world.
DrugsData, a project of Erowid Center, needs the support of professionals, students, parents, individuals with means, and small foundations for a total yearly budget of around $120,000 USD. Erowid Center's general budget and the co-pays we require fund most of this cost.
Two submission forms were submitted with these samples, one for material sold as MDMA and described as ''white powder/crystals blue tint'', and the other one for material sold as 2C-B and described as ''white powder''.
The submission form for the material sold as MDMA and described as ''white powder/crystals blue tint'' accompanied the soft white powder. The material sold as 2C-B and described as ''white powder'' accompanied the purplish/brownish crystalline powder.
Because of the actual content of these two powders -- GC/MS showed the purplish/brownish crystalline powder to be MDMA, and the soft white powder to be 2C-B -- it is the DrugsData crew's belief that each submission form arrived at the lab accompanying the wrong powder, that they effectively arrived switched.
We've confirmed these are a sample of MDMA and a sample of 2C-B. If you sent in these two samples, the descriptions of the physical characteristics of the powders might reassure you that the submission forms were switched. Or, you can reagent-test them to distinguish the MDMA from the 2C-B to be double sure.
*tl;dr This purplish crystalline powder, confirmed to be MDMA, arrived at the lab with a submission form for a sample sold as 2C-B.*
Contact info (at) drugsdata (dot) org about samples #15399 and #15400 if you have any questions.